The drug Jintropin® is a somatropin synthesized using recombinant technologies, identical to human growth hormone.
It has a pronounced effect on the metabolism of fats, proteins and carbohydrates. In children with endogenous growth hormone deficiency, somatropin stimulates the growth of skeletal bones in length, acting on the epiphysis plates of the tubular bones.
In adults and children, somatropin helps to normalize body structure by increasing muscle mass and reducing body fat. Visceral adipose tissue is especially sensitive to somatropin. Somatropin stimulates lipolysis and reduces the supply of triglycerides to fat depots.
Somatropin increases the concentration of insulin-like growth factor I (IGF-I) and its binding protein, insulin-like growth factor binding protein (IRFSB-3) in blood serum.
hypersensitivity to somatropin or any other component of the drug;
active malignant neoplasms of any localization;
signs of brain tumor growth (antitumor therapy should be completed before starting treatment with somatropin, treatment should be stopped if signs of tumor growth appear);
acute emergency conditions (including those developed as a result of complications after heart or abdominal surgery, multiple injuries, acute respiratory failure);
severe obesity (body weight / height ratio over 200%);
severe respiratory impairment in patients with Prader-Willi syndrome;
growth stimulation in patients with closed epiphyseal growth zones;
the period of breastfeeding (during treatment, breastfeeding must be stopped).
With caution: diabetes mellitus, intracranial hypertension, hypothyroidism (including when carrying out replacement therapy with thyroid hormones), concomitant therapy with GCS.
For patients with growth hormone deficiency, a deficit in the volume of extracellular fluid is characteristic. After starting treatment with somatropin, this deficiency is quickly restored. In adult patients, side effects due to fluid retention (peripheral edema, skeletal muscle rigidity, arthralgia, myalgia, paresthesia) are characteristic. These phenomena are usually mild to moderate, appear in the first months of treatment and subside spontaneously or after reducing the dose of the drug.
The frequency of these side effects depends on the dose of somatropin, the age of the patients and, possibly, is inversely proportional to the age at which growth hormone deficiency occurs. These side effects are rare in children.